Form 4: Karyopharm Therapeutics CEO Richard Paulson Sells Shares to Cover Tax Obligations

Richard Paulson, CEO of Karyopharm Therapeutics, sold 3,592 shares of common stock on June 4, 2024, to cover withholding tax obligations.

Summary

• Richard A. Paulson, the President and CEO of Karyopharm Therapeutics Inc., sold 3,592 shares of common stock on June 4, 2024.
• The sale was executed at a price of $0.99 per share.
• The transaction was conducted under a pre-arranged automatic sale plan adopted on June 10, 2021, to cover withholding tax liabilities from vesting restricted stock units.
• Following the transaction, Paulson directly owns 1,150,105 shares of Karyopharm Therapeutics Inc.

Sentiment

Score: 5

Explanation: Neutral sentiment as the transaction is related to tax obligations and executed under a pre-arranged plan, not necessarily indicative of the executive's view on the company's future performance.

Industry Context

This is a routine Form 4 filing, indicating insider transactions. It's common for executives to sell shares to cover tax obligations, especially after vesting of stock options or restricted stock units. The existence of a pre-arranged trading plan suggests the sale was not based on current market conditions or inside information.

Stakeholder Impact

• The sale of shares by the CEO could have a minor negative impact on shareholder sentiment, although it is likely to be minimal given the reason for the sale and the relatively small number of shares involved.

Key Dates